JAK inhibitor treatment-resistant splenomegaly before transplantation in myelofibrosis: Splenectomy or radiotherapy?
- PMID: 38482991
- DOI: 10.1002/ajh.27292
JAK inhibitor treatment-resistant splenomegaly before transplantation in myelofibrosis: Splenectomy or radiotherapy?
Comment on
-
Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: A global collaborative analysis.Am J Hematol. 2024 May;99(5):844-853. doi: 10.1002/ajh.27252. Epub 2024 Feb 15. Am J Hematol. 2024. PMID: 38357714
References
REFERENCES
-
- Gagelmann N, Hobbs GS, Campodonico E, et al. Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: a global collaborative analysis. Am J Hematol. 2024;99(5):844‐853. doi:10.1002/ajh.27252
-
- Kröger N, Wolschke C, Gagelmann N. How I treat transplant‐eligible patients with myelofibrosis. Blood. 2023;142(20):1683‐1696. doi:10.1182/blood.2023021218
-
- Alchalby H, Yunus DR, Zabelina T, Ayuk F, Kröger N. Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis. Bone Marrow Transplant. 2016;51(9):1223‐1227. doi:10.1038/bmt.2016.98
-
- Akpek G, Pasquini MC, Logan B, et al. Effects of spleen status on early outcomes after hematopoietic cell transplantation. Bone Marrow Transplant. 2013;48(6):825‐831. doi:10.1038/bmt.2012.249
-
- Kröger N, Sbianchi G, Sirait T, et al. Impact of prior JAK‐inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT. Leukemia. 2021;35(12):3551‐3560. doi:10.1038/s41375‐021‐01276‐4
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
